Zoetis (ZTS) shares have been impacted by a decline in the company's growth outlook, with stocks reaching a new 52-week low following the revision of earnings projections for 2025. Despite robust Q3 2025 revenues, shares tumbled after margin expansion did not convince shareholders over slower growth. The company's Q3 results were in line with expectations, but the stock still dropped. Predictions suggest Wall Street expects earnings growth for the company.
The approval of Portela in the EU could be a key component of Zoetis' pet health pipeline, yet the impact on the company's innovation remains uncertain. Zoetis reported mixed Q3 results, with earnings surpassing expectations, but revenue falling short. Despite the challenges, Zoetis retains a strong position in the market, particularly due to recent approval of new therapies such as Lenivia for osteoarthritis.
A significant amount of shares were sold, impacting the stock performance despite earnings surpassing estimates. The company managed to achieve EPS of $1.63 and revenue of $2.4 billion in Q3, slightly missing expectations.
Zoetis ZTS News Analytics from Mon, 16 Jun 2025 07:00:00 GMT to Sat, 08 Nov 2025 09:37:01 GMT - Rating -3 - Innovation 0 - Information 4 - Rumor -2
